Related Articles
Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer
Effects of p38MAPK‑mediated excision repair cross‑complementation 1 expression on prognosis of patients with non‑small cell lung cancer
Demethoxycurcumin increases the sensitivity of cisplatin‑resistant non‑small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway
Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression
Excision-repair cross-complementing 1 predicts response to cisplatin-based neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma